Compounds and compositions for intracellular delivery of therapeutic agents
US-9868692-B2 · Jan 16, 2018 · US
US9434702B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9434702-B2 |
| Application number | US-201314378825-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2013 |
| Priority date | Feb 15, 2012 |
| Publication date | Sep 6, 2016 |
| Grant date | Sep 6, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed is a new method for preparing a methyl substitute of a linezolid intermediate, (S)-2-(3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazoline) (I), wherein the intermediate (I) is obtained by the cyclization of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III). This process has a short process route, low cost, easy operation, and high yield, so is suitable for a large-scale industrial production.
Opening claim text (preview).
The invention claimed is: 1. A process for preparing an intermediate of Linezolid of Formula (I): the process comprises the following steps: a cyclization reaction of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III) is performed to obtain the compound of Formula (I), wherein R is a protected amino group as follows: 2. The process according to claim 1 , wherein the cyclization reaction is performed in the presence of a catalyst, preferably, the catalyst is a Lewis acid or a mixture thereof. 3. The process according to claim 2 , wherein the catalyst is selected from lithium bromide, magnesium bromide, lithium chloride, magnesium chloride, magnesium iodide, lithium iodide, lithium chloride, zinc chloride, tetra-n-butylammonium bromide, tetra-n-butylammonium chloride, or any mixture thereof. 4. The process according to claim 2 , wherein the catalyst is selected from lithium bromide, magnesium bromide, magnesium iodide, or any mixture thereof. 5. The process according to claim 1 , wherein the cyclization reaction is performed in a solvent, preferably, the solvent is an aprotic solvent or a mixture thereof. 6. The process according to claim 5 , wherein the aprotic solvent includes but not limited to petroleum ether, ethyl acetate, isoamyl acetate, butyl acetate, toluene, xylene, chlorobenzene, tetrahydrofuran, dichloromethane, N, N-dimethylformamide, C 6 -C 8 alkanes, acetone, 1,4-dioxane, acetonitrile, or any mixture thereof. 7. The process according to claim 1 , wherein the temperature of the cyclization reaction is in the range of 60° C.-150° C. 8. The process according to claim 7 , wherein the temperature of the cyclization reaction is in the range of 100-140° C., particularly preferably 115-125° C. 9. A process for preparing linezolid, wherein linezolid is prepared from the intermediate of Formula (I) wherein the intermediate of Formula (I) is prepared by the reaction as follows: a cyclization reaction of 3-fluoro-4-morpholinophenyl isocyanate (II) and epoxy compound (III) is performed to obtain the compound of Formula (I), wherein R is a protected amino group as follows: followed by deprotection and acetylation to obtain linezolid.
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
attached in position 2 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.